WBRT & Erlotinib in Advanced NSCLC and Brain Metastases
Status:
Terminated
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Erlotinib may stop
the growth of tumor cells by blocking some of the enzymes needed for cell growth. Erlotinib
may also make tumor cells more sensitive to radiation therapy. It is not yet known whether
giving whole-brain radiation therapy together with erlotinib is more effective than
whole-brain radiation therapy alone in treating patients with non-small cell lung cancer and
brain metastases.
PURPOSE: This randomized phase II trial is studying whole-brain radiation therapy and
erlotinib to see how well they work compared with whole-brain radiation therapy alone in
treating patients with advanced non-small cell lung cancer and brain metastases.